We therefore performed a real world analysis utilizing National Cancer Database (NCDB) to estimate the overall impact of adjuvant CET compared to ET alone on OS in women age > 50 with HR+/HER2‐pT1‐2N0M0 BC and RS ≥26. The gene discussed is ERBB2; the disease is breast cancer.